Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Artesunate in Advanced Hepatocellular Carcinoma
NCT02304289Phase 1Terminated
- Sponsor
- Ghent University Hospital
- Start
- Nov 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of artesunate in hepatocellular carcinoma (HCC), sponsored by Ghent University Hospital. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 14 days, Maximum Tolerated Dose at 14 days and 1 more. Started Nov 2014; status: terminated.
02
Drugs
artesunate
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02304289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304289.